Almac partners with Merck KGaA and the MRC to assess markers of response to Cetuximab therapy

14-Apr-2010 - United Kingdom

Almac, Merck KGaA, Darmstadt, Germany, and the Medical Research Council (MRC) have entered into a partnership to undertake a study in metastatic colorectal cancer (mCRC) using samples from the MRC COIN trial. The aim of the study is to assess potential biomarkers of response to cetuximab (Erbitux®).

Almac will utilise samples from the COIN trial to carry out quantitative polymerase chain reaction profiling and data analysis to assess other potential biomarkers in the context of combination therapy with cetuximab.

Prof. Tim Maughan, Director, Wales Cancer Trials Unit, explained: “The MRC COIN trial is the largest trial of therapy in patients with advanced colorectal cancer and tested the addition of cetuximab to oxaliplatin based chemotherapy regimen. This collaboration will enable us to identify whether biomarkers apart from the Kras status alone further define which patients may benefit most from the addition of cetuximab to chemotherapy”

Prof. Paul Harkin, president of Almac Diagnostics, said: “Almac are delighted to once again be involved in such an important study. The use of retrospective analysis from formalin fixed paraffin embedded samples will be one of the keys to successfully delivering better molecular diagnostics, which is paramount in the development of personalised medicine”

The MRC COIN study is a phase III, multicentre, three arm study in 1st-line treatment of mCRC. The study focuses on examining whether the combination of oxaliplatin and cetuximab with fluoropyrimidine chemotherapy improves patient outcomes.

https://www.bionity.com/en/news/116128/almac-partners-with-merck-kgaa-and-the-mrc-to-assess-markers-of-response-to-cetuximab-therapy.html